Related Experiment Video
Updated: May 26, 2026
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Management of myelofibrosis
1Section of Hematology, Department of Critical Care, University of Florence, Florence, Italy. amvannucchi@unifi.it
Hematology. American Society of Hematology. Education Program
|December 14, 2011
Summary
Myelofibrosis (MF) is a severe blood cancer with limited treatment options. While JAK2 inhibitors and other agents offer symptomatic relief, a cure for MF remains elusive, necessitating further research.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myelofibrosis (MF) is a serious chronic myeloproliferative neoplasm impacting survival and quality of life.
- Patients face significant clinical challenges due to limited efficacy of current therapies like medical treatment, surgery, and radiotherapy.
- Risk stratification systems (IPSS, DIPSS, DIPSS Plus) guide therapeutic decisions, including allogeneic stem cell transplantation (SCT), the only curative option with associated risks.
Purpose of the Study:
- To review the current landscape of Myelofibrosis (MF) treatment.
- To discuss the efficacy and limitations of existing and emerging therapies.
- To highlight the unmet need for curative treatments for MF.
Main Methods:
- Review of current medical literature on Myelofibrosis (MF) treatments.
- Analysis of clinical trial data for JAK2 inhibitors and other targeted agents.
- Evaluation of risk stratification systems in MF patient management.
Main Results:
- JAK2 inhibitors have shown meaningful symptomatic improvement and reduction in splenomegaly in MF patients.
- Other agents like mTOR and HDAC inhibitors, and Pomalidomide, demonstrate symptomatic efficacy, particularly for anemia.
- Current therapies are largely palliative, with limited impact on reducing the burden of mutated cells in MF.
Conclusions:
- While JAK2 inhibitors and other novel agents improve symptoms and quality of life in MF, they do not offer a cure.
- Significant unmet needs remain in MF treatment, particularly in reducing the mutated cell burden.
- Further research is crucial to develop curative strategies for Myelofibrosis.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...